Zoledronic acid prevents the hepatic changes associated with high fat diet in rats; the potential role of mevalonic acid pathway in nonalcoholic steatohepatitis.
This study investigated the hepatoprotective effect of mevalonic acid pathway inhibition by Zoledronic acid (ZA) on the hepatic changes associated with high fat diet (HFD) in rats.Thirty two male Wistar rats were used. They were divided into 2 groups: (I) control naïve (II) NASH: induced by HFD for 12 weeks, this group is subdivided into (A) NASH untreated (B)NASH + ZA (50ug/kg/week) i.p. for 12 weeks (C) NASH + ZA (100μg/kg/week) i.p. for 12 weeks. Portal pressure (PP), liver enzymes AST and ALT, serum glucose, lipid profile, hepatic levels of tumor necrosis factor alpha (TNF-α), vascular...
Source: European Journal of Pharmacology - June 21, 2019 Category: Drugs & Pharmacology Authors: Mohamed RH, Tarek M, Hamam GG, Ezzat SF Tags: Eur J Pharmacol Source Type: research

Multimodal therapy in urachal carcinoma with oligometastatic bone disease
Publication date: Available online 14 June 2019Source: Urology Case ReportsAuthor(s): C. García Alvarez, R.J. González Alvarez, A.C. Plata Bello, H. Alvarez-Argüelles Cabrera, D. Castro Díaz, T. Concepción MasipAbstractA 35-year-old male patient was admitted to our hospital for urachal carcinoma with oligometastatic bone disease. He received a surgical resection through the umbilical area, urachal ligament and bladder dome (partial cystectomy) and adjuvant chemotherapy based on cisplatin-gemcitabine regimens together zoledronic acid with a good tolerance, no toxicity. Nine months after surg...
Source: Urology Case Reports - June 16, 2019 Category: Urology & Nephrology Source Type: research

Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis
AbstractGlucocorticoids (GCs) are often used for improvement of quality of life, particularly in the elderly, but long-term GC use may cause harm; bone loss and fractures are among the most devastating side effects. Fracture risk is particularly high in patients with a severe underlying disease with an urgent need for treatment with high-dose GCs. Moreover, it is important to realize that these patients suffer from an augmented background fracture risk as these patients have a high presence of traditional risk factors for osteoporosis, such as high age, low body mass index (BMI), smoking and relatives with osteoporosis or ...
Source: Drugs - June 14, 2019 Category: Drugs & Pharmacology Source Type: research

Deciphering preferred solid-state conformations in nitrogen-containing bisphosphonates and their coordination compounds. A case study of discrete Cu(II) complexes based on C α-substituted analogues of zoledronic acid: crystal structures and solid state characterization
CrystEngComm, 2019, Accepted Manuscript DOI: 10.1039/C9CE00614A, PaperTomasz Rojek, Waldemar Goldeman, Katarzyna Ślepokura, Wiktor Zierkiewicz, Ewa Matczak-Jon Crystal structures retrieved from the CSD have been used to evaluate conformational preferences of N-containing bisphosphonic acids and related HnL(4-n)- (n = 0-4) anions within their metal complexes and salts.... The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - CrystEngComm latest articles)
Source: RSC - CrystEngComm latest articles - June 12, 2019 Category: Chemistry Authors: Tomasz Rojek Source Type: research

Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone
ConclusionThe selective CatK inhibitor may prevent the establishment and progression of PCa in bone, thus making it a novel therapeutic approach for advanced PCa. (Source: Journal of Cancer Research and Clinical Oncology)
Source: Journal of Cancer Research and Clinical Oncology - June 6, 2019 Category: Cancer & Oncology Source Type: research

Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.
CONCLUSION: The selective CatK inhibitor may prevent the establishment and progression of PCa in bone, thus making it a novel therapeutic approach for advanced PCa. PMID: 31172267 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - June 6, 2019 Category: Cancer & Oncology Authors: Liang W, Wang F, Chen Q, Dai J, Escara-Wilke J, Keller ET, Zimmermann J, Hong N, Lu Y, Zhang J Tags: J Cancer Res Clin Oncol Source Type: research

Secondary prevention of osteoporotic fractures: evaluation of the Lille University Hospital ’s Fracture Liaison Service between January 2016 and January 2018
ConclusionsSecondary prevention of osteoporotic fractures has improved since the implementation of the FLS. However, patient identification, patient evaluation, and post-fracture assessment timing still need to be improved. (Source: Osteoporosis International)
Source: Osteoporosis International - June 5, 2019 Category: Orthopaedics Source Type: research

Zoledronic acid exhibits radio-sensitizing activity in human pancreatic cancer cells via inactivation of STAT3/NF- & kappa;B signaling
(Source: OncoTargets and Therapy)
Source: OncoTargets and Therapy - June 4, 2019 Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial
The aim of the study is to analyse whether letrozole (L) and zoledronic acid plus L (ZL) are more effective than tamoxifen (T) as adjuvant endocrine treatment of premenopausal patients with breast cancer with hormone receptor –positive (HR+) tumours. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 1, 2019 Category: Cancer & Oncology Authors: Francesco Perrone, Michelino De Laurentiis, Sabino De Placido, Michele Orditura, Saverio Cinieri, Ferdinando Riccardi, Angela Stefania Ribecco, Carlo Putzu, Lucia Del Mastro, Emanuela Rossi, Vincenza Tinessa, Anna Maria Mosconi, Francesco Nuzzo, Francesca Tags: Original Research Source Type: research

Diffuse, fracturing systemic skeletal histiocytosis of unknown type: a novel metabolic bone disease
AbstractWe  describe a novel disease of diffuse skeletal histiocytosis associated with multiple fragility fractures and high osteoclast activity. Clinical, radiographic, biochemical, genetic, and histopathological investigations were performed to characterize the diagnosis of an Asian man who presented with h ip fracture and diffuse skeletal lytic lesions. After excluding malignancy and other common metabolic bone diseases, open bone biopsy yielded several pathological samples all showing extensive skeletal histiocytosis likely to explain the diffuse axial and appendicular lytic lesions. Rare disorders s uch as Langer...
Source: Osteoporosis International - May 30, 2019 Category: Orthopaedics Source Type: research

Multifunctional gelatin–tricalcium phosphate porous nanocomposite scaffolds for tissue engineering and local drug delivery: In vitro and in vivo studies
Publication date: Available online 27 May 2019Source: Journal of the Taiwan Institute of Chemical EngineersAuthor(s): Mehdi Rahmanian, Amir seyfoori, Mohammad Mehdi Dehghan, Leila Eini, Seyed Morteza Naghib, Hossein Gholami, Saeed Farzad, Kaveh Rahimi Mamaghani, Keivan Majidzadeh-AAbstractBone is known as the most prevalent, metastatic site of breast cancer; however, it's mechanism details are unknown, so developing a suitable scaffold for bone defect regeneration and sustain drug release after tumor resection can considerably inhibit the tumor recurrence after a while. Here, synthesized gelatin/beta-tricalcium phosphate (...
Source: Journal of the Taiwan Institute of Chemical Engineers - May 29, 2019 Category: Chemistry Source Type: research

Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models
ABSTRACTMultiple myeloma is a plasma cell malignancy, which develops in the bone marrow and frequently leads to severe bone destruction. Current antiresorptive therapies to treat the bone disease do little to repair damaged bone; therefore, new treatment strategies incorporating bone anabolic therapies are urgently required. We hypothesized that combination therapy using the standard of care antiresorptive zoledronic acid (Zol) with a bone anabolic (anti ‐TGFβ/1D11) would be more effective at treating myeloma‐induced bone disease than Zol therapy alone. JJN3 myeloma‐bearing mice (n = 8/group) treat...
Source: Journal of Bone and Mineral Research - May 27, 2019 Category: Orthopaedics Authors: Julia Paton ‐Hough, Simon Tazzyman, Holly Evans, Darren Lath, Jenny M Down, Alanna C Green, John A Snowden, Andrew D Chantry, Michelle A Lawson Tags: Original Article Source Type: research

Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON ‐PFT Extension I Trials
We examined the proportion of participants with BMD loss or PINP gain ≥ least significant change (LSC) and those whose va lues exceeded a threshold (T‐score ≤–2.5 or PINP ≥36.0 ng/mL, a premenopausal median value). After 3 years of placebo, the FLEX group had greater mean total hip BMD decreases (–2.3% versus –1.2% in the HORIZON‐PFT E1 group,p 
Source: Journal of Bone and Mineral Research - May 27, 2019 Category: Orthopaedics Authors: Tiffany Y Kim, Douglas C Bauer, Brian L McNabb, Anne L Schafer, Felicia Cosman, Dennis M Black, Richard Eastell Tags: Original Article Source Type: research

Evaluation of therapeutic effects of teriparatide in a rat model of zoledronic acid-induced bisphosphonate-related osteonecrosis
In conclusion, ZOL has negative effects on osteoclasts. TPTD was found to be effective in eliminating the negative effects of ZOL. TPTD had positive effects in preventing bone resorption and promoting osteogenesis. In addition, TPTD improved osteoclastogenesis, which in turn led to the improvement of BRON. (Source: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology)
Source: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology - May 23, 2019 Category: ENT & OMF Source Type: research

Systemic sclerostin antibody treatment increases osseointegration and biomechanical competence of zoledronic-acid-coated dental implants in a rat osteoporosis model.
Authors: Korn P, Kramer I, Schlottig F, Tödtman N, Eckelt U, Bürki A, Ferguson SJ, Kautz A, Schnabelrauch M, Range U, Kneissel M, Stadlinger B Abstract Osseointegration of dental implants can be promoted by implant-surface modifications using bisphosphonate coatings. In addition, it is of clinical interest to promote peri-implant bone formation and to restore bony structure in low bone-mass patients. The present study evaluated a combination of an anti-resorptive zoledronic acid (ZOL) implant-coating and a systemically applied sclerostin antibody, a known bone anabolic treatment principle, versus sole scl...
Source: European Cells and Materials - May 22, 2019 Category: Cytology Tags: Eur Cell Mater Source Type: research

Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis
ConclusionsReceiving an intravenous infusion of 5  mg zoledronic acid after THA can effectively reduce periprosthetic BMD loss and improve bone remodeling in females with postmenopausal osteoporosis.SummaryZoledronic acid significantly inhibited bone mass loss in zones 1, 2, 4, 6, and 7 after THA and inhibited bone-resorption marker ( β-CTX) to improve bone remodeling. Zoledronic acid treatment is potentially important for patients with osteoporosis after THA. (Source: Osteoporosis International)
Source: Osteoporosis International - May 21, 2019 Category: Orthopaedics Source Type: research

Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Authors: Gallicchio R, Mastrangelo PA, Nardelli A, Mainenti PP, Colasurdo AP, Landriscina M, Guglielmi G, Storto G Abstract Radium-223 dichloride (223Ra) is the first, recently approved, α-particle-emitting radiopharmaceutical for the treatment of patients with bone metastases in castration-resistant prostate cancer (CRPC) and no evidence of visceral metastases. We explored MEDLINE, relevant congresses, and websites for data on 223Ra and prostate cancer therapies, focusing on therapeutic strategies and timing, bone metastases, and diagnostic assessment. 223Ra represents the only bone-targeting agent that has ...
Source: Tumori - May 19, 2019 Category: Cancer & Oncology Tags: Tumori Source Type: research

Author Correction: Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid in vitro
Acta Pharmacologica Sinica, Published online: 16 May 2019; doi:10.1038/s41401-019-0232-xAuthor Correction: Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid in vitro (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - May 16, 2019 Category: Drugs & Pharmacology Authors: Han Qiao Ting-yu Wang Wei Yan An Qin Qi-ming Fan Xiu-guo Han Yu-gang Wang Ting-ting Tang Source Type: research

Author Correction: Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid in vitro.
Abstract The authors regretted to find the mis-representative images in Fig. 3a, c and Fig. 4a, c when re-read our previously published article Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro (DOI: 10.1038/aps.2015.42) in the journal of Acta Pharmacologica Sinica. This mistake occurred due to the careless compilation when the authors tried to show the synergistic effect against tumor apoptosis during figure presentation process. The right Fig. 3a, c and Fig. 4a, c were provided below. Despite that this correction does not affect the results and conclusi...
Source: Acta Pharmacologica Sinica - May 16, 2019 Category: Drugs & Pharmacology Authors: Qiao H, Wang TY, Yan W, Qin A, Fan QM, Han XG, Wang YG, Tang TT Tags: Acta Pharmacol Sin Source Type: research

Drug repurposing to overcome resistance to various therapies for colorectal cancer.
Abstract Emergence of novel treatment modalities provides effective therapeutic options, apart from conventional cytotoxic chemotherapy, to fight against colorectal cancer. Unfortunately, drug resistance remains a huge challenge in clinics, leading to invariable occurrence of disease progression after treatment initiation. While novel drug development is unfavorable in terms of time frame and costs, drug repurposing is one of the promising strategies to combat resistance. This approach refers to the application of clinically available drugs to treat a different disease. With the well-established safety profile and...
Source: Cellular and Molecular Life Sciences : CMLS - May 13, 2019 Category: Cytology Authors: Fong W, To KKW Tags: Cell Mol Life Sci Source Type: research

Retraction Note: Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model
Retraction Note: Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model, Published online: 08 May 2019; doi:10.1038/s41419-019-1606-1Retraction Note: Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model (Source: Cell death and disease)
Source: Cell death and disease - May 8, 2019 Category: Internal Medicine Authors: H. Qiao T. Y. Wang Z. F. Yu X. G. Han X. Q. Liu Y. G. Wang Q. M. Fan A. Qin T. T. Tang Source Type: research

Romosozumab (Evenity) for Postmenopausal Osteoporosis
Date: June 3, 2019 Issue #:  1573Summary:  The FDA has approved romosozumab-aqqg (Evenity– Amgen), a sclerostin inhibitor, for once-monthly subcutaneous (SC) treatment of osteoporosis in postmenopausal women who are at high risk for fracture (history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or cannot tolerate other drugs for this indication. R omosozumab is the first sclerostin inhibitor to be approved in the US and the third drug for treatment of postmenopausal osteoporosis that stimulates bone formation; the parathyroid hormone (PTH) receptor ag...
Source: The Medical Letter - May 1, 2019 Category: Drugs & Pharmacology Authors: admin Tags: abaloparatide Aclasta Actonel Alendronate Atelvia Binosto Bisphosphonates Boniva Denosumab Evenity Evista Forteo Fosamax Fosavance Ibandronate Osteoporosis Postmenopausal osteoporosis Prolia Raloxifene Reclast rised Source Type: research

Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report.
Abstract The combination of cetuximab (CTX) and chemotherapy, such as FOLFOX or FOLFIRI, is currently the standard treatment for metastatic colorectal cancer (mCRC). Zoledronic acid (ZOL) is used in patients with bone metastasis. We herein report our experience with the case of a 58-year-old male patient with metastatic rectal cancer who was treated with ZOL + CTX as third-line therapy, and in whom this combination appeared to be effective. Although the patient developed bone metastasis and cardiac tamponade due to the recurrence of rectal cancer, he survived for approximately 10 months after the initiation of ZOL...
Source: Clinical Colorectal Cancer - May 1, 2019 Category: Cancer & Oncology Authors: Tokumaru Y, Matsuhashi N, Takahashi T, Tanahashi T, Matsui S, Imai H, Tanaka Y, Yamaguchi K, Yoshida K Tags: Mol Clin Oncol Source Type: research

Clinical effect observation of intravenous application of zoledronic acid in patients with cervical spondylosis and osteoporosis after anterior cervical discectomy and fusion: A randomized controlled study.
Abstract OBJECTIVE: To observe the clinical effect of zoledronic acid (ZA) in patients with cervical spondylosis and osteoporosis after anterior cervical discectomy and fusion (ACDF) surgery. METHODS: All selected patients were divided into the study group and the control group according to the sequence of surgery time. In the study group, 5 mg (100 ml) of ZA was applied intravenously as intervention on the 5 day after ACDF surgery. Patients were followed up regularly after surgery. RESULTS: Forty-three cases completed the follow-ups (21/22), the neck disability index (NDI) score significantly decreased ...
Source: Journal of Orthopaedic Surgery - May 1, 2019 Category: Orthopaedics Authors: Liu B, Liu X, Chen Y, Wang G, Wang G, Shen X, Liu H, Liao X Tags: J Orthop Surg (Hong Kong) Source Type: research

Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.
CONCLUSION: Adjuvant treatment with zoledronic acid did not decrease the recurrence rate of GCTB in this study. The efficacy could not be determined because of the small sample size. Because recurrences, even in the denosumab era, are still an issue, a randomized study exploring the efficacy of zoledronic acid in the adjuvant setting in GCTB is still valid. PMID: 31040253 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - April 30, 2019 Category: Cancer & Oncology Authors: Lipplaa A, Kroep JR, van der Heijden L, Jutte PC, Hogendoorn PCW, Dijkstra S, Gelderblom H Tags: Oncologist Source Type: research

Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
Abstract Hutchinson-Gilford progeria syndrome (HGPS) is a rare, premature ageing syndrome in children. HGPS is normally caused by a mutation in the LMNA gene, encoding nuclear lamin A. The classical mutation in HGPS leads to the production of a toxic truncated version of lamin A, progerin, which retains a farnesyl group. Farnesyltransferase inhibitors (FTI), pravastatin and zoledronic acid have been used in clinical trials to target the mevalonate pathway in HGPS patients to inhibit farnesylation of progerin, in order to reduce its toxicity. Some other compounds that have been suggested as treatments include rapam...
Source: Biogerontology - April 30, 2019 Category: Geriatrics Authors: Clements CS, Bikkul MU, Ofosu W, Eskiw C, Tree D, Makarov E, Kill IR, Bridger JM Tags: Biogerontology Source Type: research

Effects of zoledronic acid and dexamethasone on early phases of socket healing after tooth extraction in rats: A preliminary macroscopic and microscopic quantitative study.
CONCLUSIONS: Our findings confirmed that exposure to ZOL plus DEX impairs alveolar wound repair. Inhibition of osteoclastic resorption of socket walls after tooth extraction and the inability to dispose of the necrotic bone may be considered the initial steps of MRONJ onset. PMID: 31011145 [PubMed - as supplied by publisher] (Source: Medicina Oral, Patologia Oral y Cirugia Bucal)
Source: Medicina Oral, Patologia Oral y Cirugia Bucal - April 24, 2019 Category: ENT & OMF Tags: Med Oral Patol Oral Cir Bucal Source Type: research

Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Conclusion: Long-term alendronate and zoledronic acid therapies reduce fracture risk in women with osteoporosis. Long-term bisphosphonate treatment may increase risk for rare adverse events, and continuing treatment beyond 3 to 5 years may reduce risk for vertebral fractures. Long-term hormone therapy reduces hip fracture risks but has serious harms. Primary Funding Source: National Institutes of Health and Agency for Healthcare Research and Quality. (PROSPERO: CRD42018087006). PMID: 31009947 [PubMed - as supplied by publisher] (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - April 23, 2019 Category: Internal Medicine Authors: Fink HA, MacDonald R, Forte ML, Rosebush CE, Ensrud KE, Schousboe JT, Nelson VA, Ullman K, Butler M, Olson CM, Taylor BC, Brasure M, Wilt TJ Tags: Ann Intern Med Source Type: research

RETRACTED: Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial
Publication date: April 2019Source: Journal of Bone Oncology, Volume 15Author(s): Shenglong Li, Peng Chen, Qiankun YangAbstractBackgroundAlthough denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven.ObjectivesTo compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with surgically unsalvageable giant cell tumor of bone.MethodsA total of 250 patients with surgically unsalvageable giant cell tumor of bone were included in this randomized clinical trial. Patients received either subcutaneous denosumab (DB group; 120 mg per 4 we...
Source: Journal of Bone Oncology - April 13, 2019 Category: Cancer & Oncology Source Type: research

Effect of Cervus and Cucumis Polypeptide Combined with Zoledronic Acid on Bone Metabolic Biochemical Markers in Glucocorticoids - Induced Osteoporosis Patients
Publication date: Available online 11 April 2019Source: Saudi Journal of Biological SciencesAuthor(s): Dacheng Han, Anhua Long, Jialong Wang, Xuefei Wang, Yakui ZhangAbstractObjectiveTo investigate the effect of cervus and cucumis polypeptide combined with zoledronic acid on bone metabolic biochemical markers in glucocorticoids - induced osteoporosis patients.MethodsA total of 100 patients with glucocorticoids - induced osteoporosis admitted to our hospital from January 2015 to June 2017 were enrolled in this study. Patients were divided into observation group and control group by random number table method, 50 cases in ea...
Source: Saudi Journal of Biological Sciences - April 13, 2019 Category: Biology Source Type: research

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.
CONCLUSIONS: Denosumab is cost-effective versus ZA for SRE prevention in patients with MM in Austria, Belgium, Greece, and Italy, based on often-adopted World Health Organization thresholds. This conclusion is robust to changes in model parameters and assumptions. Cost-effectiveness estimates varied across the four countries, reflecting differences in healthcare costs and national economic evaluation guidelines. PMID: 30969797 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 12, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Zoledronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic compression fracture in a single T12 or L1 vertebral body in postmenopausal women
AbstractSummaryWe performed a 1-year prospective study to see whether zoledronic acid infusion combined with percutaneous kyphoplasty could provide more benefits in the treatment of T12 or L1 osteoporotic vertebral compression fracture (OVCF).IntroductionTo investigate and analyze the clinical effects of zoledronic acid (ZOL) in combination with percutaneous kyphoplasty (PKP) in the treatment of OVCF in postmenopausal women.MethodsIncluded in this study were 101 postmenopausal women patients with T12 or L1 OVCF who received PKP in our hospital between August 2015 and July 2017. They were randomly assigned to a zoledronic a...
Source: Osteoporosis International - April 11, 2019 Category: Orthopaedics Source Type: research

Comparative effectiveness of alendronate and zoledronic acid on bone mass improvement in transfusion-dependent thalassemia patients
AbstractThalassemia, as the most prevalent genetic blood disorder, has many associated comorbidities including low bone mass. We studied the comparative effectiveness of alendronate (AL) and zoledronic acid (ZOL) on bone mass improvement in transfusion-dependent thalassemia (TDT) patients a year after treatment. Three hundred seventy-five TDT patients with low bone mass were enrolled in this study. After a year of treatment with either AL or ZOL, a second bone mineral density (BMD) test was ordered to compare the effectiveness of the two aforementioned drugs. Body mass index (BMI), physical activity, sun exposure, and bioc...
Source: Journal of Bone and Mineral Metabolism - April 11, 2019 Category: Orthopaedics Source Type: research

Inhibitory Effect of KP-A038 on Osteoclastogenesis and Inflammatory Bone Loss Is Associated With Downregulation of Blimp1
Hye Jung Ihn1†, Taeho Lee2†, Doohyun Lee2, Jong-Sup Bae2, Sang-Hyun Kim3, Il Ho Jang4, Yong Chul Bae5, Hong-In Shin6 and Eui Kyun Park6* 1Institute for Hard Tissue and Bio-tooth Regeneration, Kyungpook National University, Daegu, South Korea 2College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, South Korea 3Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu, South Korea 4Department of Oral Biochemistry and Molecular Biology, School of Dentistry, Pusan National University, Yangsan, South Korea 5Department of Oral ...
Source: Frontiers in Pharmacology - April 10, 2019 Category: Drugs & Pharmacology Source Type: research

National Comprehensive Cancer Network Infusion Efficiency Workgroup Study: Optimizing Patient Flow in Infusion Centers.
CONCLUSION: There is a high degree of variation among cancer centers in regard to planned chair time for the same chemotherapy regimens, providing opportunities for improved efficiency, increased revenue, and more standardization across centers. The NCCN Workgroup demonstrates potential revenue impact and provides recommendations for cancer centers to move toward more efficient and more standard practices. PMID: 30964732 [PubMed - as supplied by publisher] (Source: JOP)
Source: JOP - April 9, 2019 Category: Gastroenterology Authors: Sugalski JM, Kubal T, Mulkerin DL, Caires RL, Moore PJ, Fiorarancio Fahy R, Gordon JN, Augustyniak CZ, Szymanski GM, Olsen M, Frantz DK, Quinn MA, Kidd SK, Krause DM, Carlson RW, Stewart FM Tags: J Oncol Pract Source Type: research

Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer
AbstractAdjuvant therapy with bisphosphonates in prostate cancer is effective in improving bone mineral density and thus reducing fractures and skeletal-related events. We analyzed the effect of bisphosphonates on overall survival (OS) in subgroups of patients with prostate cancer. A systematic literature search was conducted of the PubMed database and the bibliographies of related studies. The long-term OS rates were extracted from every eligible trial. The hazard ratio (HR) was pooled with the fixed effects model, and preplanned subgroup analyses were performed. The search yielded 112 articles, of which 10 articles with ...
Source: Clinical and Experimental Metastasis - April 8, 2019 Category: Cancer & Oncology Source Type: research

Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer.
Abstract Adjuvant therapy with bisphosphonates in prostate cancer is effective in improving bone mineral density and thus reducing fractures and skeletal-related events. We analyzed the effect of bisphosphonates on overall survival (OS) in subgroups of patients with prostate cancer. A systematic literature search was conducted of the PubMed database and the bibliographies of related studies. The long-term OS rates were extracted from every eligible trial. The hazard ratio (HR) was pooled with the fixed effects model, and preplanned subgroup analyses were performed. The search yielded 112 articles, of which 10 arti...
Source: Clinical Prostate Cancer - April 8, 2019 Category: Cancer & Oncology Authors: Wu C, Chen W, Wu J, Zhang X, Huang X, Lin R, Zhu B, Jiang H Tags: Clin Exp Metastasis Source Type: research

Microcirculatory consequences of limb ischemia/reperfusion in ovariectomized rats treated with zoledronic acid
Nitrogen-containing bisphosphonates (BIS) are potent therapeutics in osteoporosis, but their use may result in osteonecrotic side-effects in the maxillofacial region. Periosteal microcirculatory reactions may ... (Source: Journal of Orthopaedic Surgery and Research)
Source: Journal of Orthopaedic Surgery and Research - April 4, 2019 Category: Orthopaedics Authors: Levente P ócs, Ágnes Janovszky, Imre Ocsovszki, József Kaszaki, József Piffkó and Andrea Szabó Tags: Research article Source Type: research

Chronic treatment with zoledronic acid alters the expression levels of inflammatory, bone, and apoptotic markers and Toll-like receptors 2 and 4 in rat dental pulp
ConclusionsZA increases the expression levels of inflammatory, apoptotic markers, and TLR4 and alters bone makers in the dentalpulp of rats. (Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology)
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - March 31, 2019 Category: ENT & OMF Source Type: research

Cost-effectiveness of standard utilization of zoledronic acid for bone metastases from advanced lung cancer in China.
CONCLUSION: Standard utilization of ZA dominated real-world utilization of ZA for BM in Chinese patients with advanced lung cancer from cost-effectiveness perspective. PMID: 30922074 [PubMed - as supplied by publisher] (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - March 30, 2019 Category: General Medicine Tags: J Comp Eff Res Source Type: research

Medication-related osteonecrosis of the jaw in a minipig model: parameters for developing a macroscopic, radiological, and microscopic grading scheme
ConclusionThese parameters were used to develop a scoring system for grading BRONJ. (Source: Journal of Cranio Maxillofacial Surgery)
Source: Journal of Cranio Maxillofacial Surgery - March 19, 2019 Category: ENT & OMF Source Type: research

The Utility of Prophylactic Zoledronic Acid in Patients Undergoing Lung Transplantation - A Retrospective Analysis
Osteoporosis is prevalent among lung transplant candidates and is exacerbated post-transplant by immunosuppressive therapy (glucocorticoids and calcineurin inhibitors). Osteoporotic fractures are a significant source of morbidity. Low bone mineral density (BMD) is a well-recognised surrogate for fracture risk. Intravenous zoledronic acid (ZA) effectively prevents the former and reduces the latter in post-menopausal osteoporosis. Many groups, ours included, prophylactically treat lung transplant recipients with bisphosphonates to prevent BMD reduction and reduce fracture rates. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: E. Ng, D. Topliss, M. Paraskeva, E. Paul, S. Sztal-Mazer Tags: 1048 Source Type: research

Role of Bisphosphonates in Breast Cancer Therapy
Opinion statementBisphosphonates are utilized routinely in breast cancer. In metastatic disease with bone involvement, bisphosphonates prevent or delay skeletal-related events and can improve pain control. Different agents have shown benefit compared with placebo or no treatment. While in unselected patients, comparison between zoledronic acid and pamidronate did not show a significant difference, exploratory analyses showed that in patients with osteolytic lesions or hypercalcemia, zoledronic acid is superior to pamidronate. De-escalating treatment with zoledronic acid from every 4 to every 12  weeks has been shown t...
Source: Current Treatment Options in Oncology - March 14, 2019 Category: Cancer & Oncology Source Type: research

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy
AbstractPurposeTumor-infiltrating lymphocytes (TILs) are associated with pathological complete response (pCR) and survival after neoadjuvant chemotherapy (NAC) in patients with early breast cancer. We investigated the prognostic and predictive role of TILs, macrophages, and HLA class 1 expression after NAC with or without the potentially immune modulating compound zoledronic acid (ZA).MethodsBaseline tumor biopsies from 196 patients in the NEOZOTAC trial were analyzed for CD8 (cytotoxic T-cells), FoxP3 (regulatory T-cells), CD68 (macrophages), and HLA class I (HCA2/HC10) expression by immunohistochemistry and subsequently ...
Source: Breast Cancer Research and Treatment - March 13, 2019 Category: Cancer & Oncology Source Type: research

Tuning of the Radium biodistribution by Dietary Supplements in a CD1 Mice Model
Although 223RaCl2 has been approved for the treatment of bone metastases originating from mCRPC (EMA, FDA and others), further data on 223Ra biodistribution and possible metabolism tuning are needed particularly after the discovery of increased risk of death and fractures due to the interactions of 223Ra with abiraterone, prednisone/prednisolone treatment. Thus we report here the results of biodistribution study with 223RaCl2 applied intravenously to a healthy female CD1 mice fed with various dietary supplements - vitamin D and CaCl2 or with co-treatment with zoledronic acid. (Source: Journal of Medical Imaging and Radiation Sciences)
Source: Journal of Medical Imaging and Radiation Sciences - March 1, 2019 Category: Radiology Authors: J án Kozempel, Ekaterina Kukleva, Jandová Ludmila, Jana Merhautová, Karolína Ficenzová, Martin Vlk, Petra Suchánková Source Type: research

mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model
Publication date: Available online 27 February 2019Source: Journal of Bone OncologyAuthor(s): Chiara Spadazzi, Federica Recine, Laura Mercatali, Giacomo Miserocchi, Chiara Liverani, Alessandro De Vita, Alberto Bongiovanni, Valentina Fausti, Toni IbrahimAbstractThe skeleton is one of the most common sites of metastatic spread from advanced clear-cell renal carcinoma (ccRCC). Most of the bone lesions observed in RCC patients are classified as osteolytic, causing severe pain and morbidity due to pathological bone destruction. Nowadays, it is well known that cancer induced bone loss in lytic metastasis is caused by the trigger...
Source: Journal of Bone Oncology - February 28, 2019 Category: Cancer & Oncology Source Type: research

Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells
Zoledronic acid (ZA), a nitrogen-containing bisphosphonate, inhibits osteoclastogenesis. Emerging evidence suggests that ZA has anti-tumor and anti-metastatic properties for breast cancer cells. In a mouse mod... (Source: BMC Cancer)
Source: BMC Cancer - February 26, 2019 Category: Cancer & Oncology Authors: Hsien Liu, Shih-Han Wang, Shin-Cheh Chen, Ching-Ying Chen and Tsun-Mei Lin Tags: Research article Source Type: research

Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline
ABSTRACTAn evidence ‐based clinical guideline for the diagnosis and management of Paget's disease of bone (PDB) was developed using GRADE methodology, by a Guideline Development Group (GDG) led by the Paget's Association (UK). A systematic review of diagnostic tests and pharmacological and nonpharmacological treatmen t options was conducted that sought to address several key questions of clinical relevance. Twelve recommendations and five conditional recommendations were made, but there was insufficient evidence to address eight of the questions posed. The following recommendations were identified as the most im portant:...
Source: Journal of Bone and Mineral Research - February 25, 2019 Category: Orthopaedics Authors: Stuart H Ralston, Luis Corral ‐Gudino, Cyrus Cooper, Roger M Francis, William D Fraser, Luigi Gennari, Núria Guañabens, M Kassim Javaid, Robert Layfield, Terence W O'Neill, R Graham G Russell, Michael D Stone, Keith Simpson, Diana Wilkins Tags: Original Article Source Type: research

Zoledronic acid inhibits the growth of cancer stem cell derived from cervical cancer cell by attenuating their stemness phenotype and inducing apoptosis and cell cycle arrest through the Erk1/2 and Akt pathways
Zoledronic acid is the most potent osteoclast inhibitor and is widely used for advanced cancer patients with bone metastasis, but its role on cancer stem cells (CSCs) remains unclear. In the present study, we ... (Source: Journal of Experimental and Clinical Cancer Research)
Source: Journal of Experimental and Clinical Cancer Research - February 21, 2019 Category: Cancer & Oncology Authors: Li Wang, Yanyang Liu, Yueling Zhou, Jiantao Wang, Li Tu, Zhen Sun, Xiujie Wang and Feng Luo Tags: Research Source Type: research